Veritas Medicine Release: OvaRex MAb For Patients With Advanced Ovarian Cancer May Extend Remission Following Favorable Surgery And Chemotherapy
10/19/2005 5:13:12 PM
BOSTON--(BUSINESS WIRE)--April 4, 2005--
U.S. Researchers Seeking New Standard of Care for Advanced Ovarian Cancer
For the majority of patients with advanced ovarian cancer, the current standard of care and front-line treatments - surgery and chemotherapy - are not enough to control the high recurrence rate. Researchers at clinical centers throughout the United States are further evaluating OvaRex(R) MAb (oregovomab), an investigational therapy, to determine the extent of remission in patients who have a favorable response to surgery and chemotherapy. They are also assessing survival, quality of life, immune response, and safety. Women with stage III or IV ovarian cancer, who qualify to participate in the ongoing clinical research, must begin taking the study medication within four to 12-weeks of completing their last dose of initial chemotherapy. For more information and pre-screening, visit www.OvarianCancerStudy.com.
According to the American Cancer Society (ACS), ovarian cancer causes more deaths than any other cancer of the female reproductive system. Because it is usually detected at an advanced stage, the disease is difficult to treat and most patients relapse within two years of front-line treatment.
comments powered by